Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Innovative Industrial Properties

Got $5,000? 3 Stocks to Buy That Could Double by 2022

The Biggest Coronavirus Vaccine Winner So Far

The announcement of a Phase 3 vaccine trial in the United Kingdom keeps Novavax in contention and shares NVAX stock on investors’ radar. The post Novavax Gains With Start of Phase 3 Vaccine Trial appeared first on InvestorPlace.

Novavax Gains With Start of Phase 3 Vaccine Trial

Big Lots

Co-Diagnostics

Textainer Group Holdings Limited

TTM Technologies

Unisys

VirnetX

Vaxart

XBiotech

These are the small cap stocks with the best value, fastest growth, and most momentum for October 2020.

Top Small Cap Stocks for October 2020

With new competition joining the fray in the Covid-19 vaccine race, NVAX stock looks vulnerable. However, the enormous complexity of this arena gives Novavax a fighting chance.

Deep Diving the Complex Narrative Behind Novavax

Endo (ENDP) and Novavax enter a manufacturing agreement for the latter's COVID-19 vaccine candidate, NVX-CoV2373.

Endo Up on COVID-19 Vaccine Manufacturing Deal with Novavax

GAITHERSBURG, Md., Sept.  28, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the Company’s COVID-19, influenza and respiratory syncytial virus (RSV) vaccines. The presentations are part of the 2020 World Vaccine Congress Washington, taking place virtually September 28-October1, 2020.

Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020

Bottom line: don't bet the ranch, but NVAX stock is a buy as it enters Phase 3 trials.
The post Novavax Stock Definitely Is Not the Long-Shot Vaccine Play You Might Think appeared first on InvestorPlace.

Novavax Stock Definitely Is Not the Long-Shot Vaccine Play You Might Think

Novavax announced that it would officially be entering Phase 3 of its COVID-19 vaccine candidate clinical trials in the U.K., with plans to begin in the United States by the end of October.

Could NVAX Have the Winning Vaccine?

Novavax’s stock price surged Friday after the biotech firm started a key late-stage trial of its experimental coronavirus vaccine. Shares in the Maryland-based company soared nearly 11 percent to $113.56 following its Thursday announcement that it kicked off the Phase 3 study in the United Kingdom, which is battling a surge in COVID-19 infections.

Novavax stock soars after start of late-stage COVID-19 vaccine trial

Endo International

Novavax Inc. (NASDAQ: NVAX) said that Endo International (NASDAQ: ENDP) will be in charge of manufacturing its COVID-19 vaccine after the two companies inked a non-exclusive agreement on Friday. Earlier this year in July, the U.S. government invested £1.27 billion in Novavax under its “Operation Warp Speed” program.

Endo International to manufacture Novavax’s candidate COVID-19 vaccine

Novavax is moving ahead with Phase 3 trials in the United Kingdom, and NVAX stock is rallying higher on the news. 
The post NVAX Stock: Novavax Rallies After Entering Phase 3 Vaccine Trials appeared first on InvestorPlace.

NVAX Stock: Novavax Rallies After Entering Phase 3 Vaccine Trials

Costco

Investors went into the weekend on an optimistic note.

Nasdaq Jumps Despite Costco Pullback; Novavax Starts Vaccine Phase 3 Trial

The two companies signed a manufacturing agreement.

Why Novavax and Endo International Stocks Are Rising Today

Novavax stock jumped as the biotech company said it will test up to 10,000 volunteers in the U.K. over the next four to six weeks in a late-stage trial of its experimental Covid-19 vaccine.
The post Novavax Initiates Late-Stage Trial Of Experimental Coronavirus Vaccine appeared first on Investor's Business Daily.

Novavax Initiates Late-Stage Trial Of Experimental Coronavirus Vaccine

Novavax, Inc. (NASDAQ: NVAX)  announced  late Thursday the initiation of a late-stage study of its investigational coronavirus vaccine, NVX-CoV2373, in the U.K.
 The Novavax Analysts: H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Novavax with a $290 price target.

Novavax Analysts Confident As Coronavirus Vaccine Candidate Heads To Phase 3 Study

In the race for a COVID vaccine it pays to keep your options open.

Coronavirus vaccine trials moving to late stage gives hope of an end to pandemic

Novavax (NVAX) starts a phase III efficacy study on its COVID-19 vaccine candidate NVX-CoV2373 in the United Kingdom. Stock rises in after-hours trading.

Novavax Begins Phase III Study on Coronavirus Vaccine in the UK

Shares of Novavax Inc. 
        NVAX, 
        +0.85% 
       jumped 6.8% in premarket trading on Friday after the company announced a COVID-19 vaccine manufacturing deal with Endo International 
        ENDP, 
        -1.46%  .
       Endo's stock is up 7.3%.

Novavax stock rises as it announces vaccine manufacturing deal with Endo

Early studies showed the potential vaccine produced "robust antibody responses" greater than those seen in recovering patients.

Second COVID-19 vaccine to begin advanced clinical trials in the UK

Novavax, Inc. said Thursday it was launching a large-scale diverse Phase 3 study of its COVID-19 vaccine in the United Kingdom — causing a more than 7% spike in the company’s shares after the closing bell.

Novavax Shares Surge 7% As It Begins Late-Stage COVID-19 Vaccine Trials

Novavax received $1.6 billion from the U.S. federal government to fund the late-stage development and production of its vaccine.

Novavax’s Coronavirus Vaccine Enters Late-Stage Trials

Event Highlighted Leadership in Vaccine Development and Regional Growth in Biotechnology Innovation Event Highlighted Leadership in Vaccine Development and Regional Growth in Biotechnology Innovation

Gov. Hogan, Novavax’ Erck, & BIO’s Dr. McMurry-Heath Toured Novavax Labs and Discussed Progress on COVID-19 Vaccine

Clinical trial to enroll up to 10,000 volunteers across the UK to assess whether NVX-CoV2373 is effective in the prevention of COVID-19 Clinical trial to enroll up to 10,000 volunteers across the UK to assess whether NVX-CoV2373 is effective in the prevention of COVID-19

Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom

NVAX stock is goign to be even more interesting in the next two months. Capacity has risen, and study progress has been made.

News for Novavax Stock (NVAX)